Bio Innovation Conference | Agenda
Presented by Maryland Life Sciences, a division of the Maryland Tech Council, the Bio Innovation Conference is driving the future of life sciences in Maryland. This conference provides a forum for professionals from industry, academia and government to discuss trends and insight into Maryland’s burgeoning life sciences industry and topics related to funding, structuring, commercialization and government relations.
Maryland Life Sciences Bio Innovation Conference, Bio Innovation Conference, Maryland, life sciences, biotechnology, Maryland Tech Council, bio, innovation, conference, Maryland Life Sciences, Bio Innovation Conference, vaccines, gene therapy, networking, Washington DC, DMV, Biohealth, biohealth capital region, sciences, entrepreneurship, entrepreneur, startup, Maryland Life Sciences Bio Innovation Conference, Maryland Tech Council Conference, annual conference
page-template,page-template-full_width,page-template-full_width-php,page,page-id-20103,ajax_fade,page_not_loaded,,qode-child-theme-ver-1.0.0,qode-theme-ver-17.2,qode-theme-bridge,qode_header_in_grid,wpb-js-composer js-comp-ver-5.6,vc_responsive


Day 1  |  October 3, 2022

7:00 am – 8:00 am Registration Open – Breakfast and Networking
8:00 am – 8:45 am Welcome and Opening Remarks

Marty Rosendale, Chief Executive Officer, Maryland Life Sciences
Mike Gill, Secretary, Maryland Department of Commerce
Brad Stewart, Senior Vice President of Business Development, Montgomery County Economic Development Corporation
Steven Walker, Senior Director, Global Marketing – Early Portfolio Strategy, GlaxoSmithKline

9:00 am – 4:00 pm BIO One-on-One Partnering
9:00 am – 9:45 am

Sponsored by

Opening Keynote  |  Innovating at NIH and Establishing ARPA-H

NIH has several new and evolving research initiatives. Several will be highlighted, including the Advanced Research Project Agency for Health (ARPA-H), a new biomedical and health research agency aimed at catalyzing breakthroughs to improve the health of all Americans; the Rapid Acceleration of Diagnostics initiative aimed at advancing innovative ideas for new COVID-19 testing approaches and strategies; and the Cancer Moonshot 2.0, which has ambitious goals to end cancer as we know it today. 

Abhishek Dhawan, Executive and Life Science Core Market Leader, DPR Construction
Tara Schwetz, Ph.D., Acting Principal Deputy Director, NIH

10:00 am – 10:45 am Expanding the Boundaries of Cell and Gene Therapy

Since 2016 there has been a renaissance in the cell and gene therapy field, building an impressive pipeline of 24 approved therapies by the FDA. Requiring decades of innovation efforts, the list of licensed products includes autologous T cell immunotherapies, AAV vector-based gene therapies, and allogeneic cell therapies. These therapies treat diverse clinical indications and tissue targets, including cancer, neuromuscular disease, neurodegenerative disease, and retinal dystrophy. This informative session features executive-level speakers from three Maryland-based biotechnology companies whose core mission is to expand boundaries to create a new generation of therapies that will enhance patient outcomes through cell engineering, RNA engineering and AAV gene therapy.

Lesley Eschinger, Director of Market Development, MaxCyte

Craig Malzahn, Senior Vice President, Technical Operations, REGENXBIO 
Dr. Milos Miljkovic, Chief Medical Officer, Cartesian Therapeutics
Cenk Sumen
, Chief Scientific Officer, MaxCyte

11:00  am – 11:45  am Factors Impacting Patient Access to Cell and Gene Therapies

Patient/doctor relationship:  challenges they go through in terms of access, getting into clinical trials, rare diseases/new diseases, how to get patients access to life saving therapies/what barriers they overcome.

Dr. Cartier Esham, Chief Scientific Officer, Biotechnology Industry Organization

Nina Hunter, Vice President of Regulatory and Science Policy, REGENXBIO 
Colin Werth
, Parent Project Muscular Dystrophy
Mark Trusheim, Strategic Director, NEWDIGS, Sloan School of Management MIT (invited)

12:00 pm – 1:30 pm Networking Lunch
1:30 pm – 2:15 pm Keys to Expand a Diverse Talent in Workforce Development

Maryland is home to more than 54,000 life sciences jobs and led the nation in science and tech workforce growth in 2021. As Maryland’s life sciences ecosystem continues to thrive, how can life sciences employers recruit, train, and empower a diverse workforce and welcome individuals from all backgrounds? With a growing body of evidence showing that diverse organizations outperform their counterparts, how can companies broaden the diversity of candidates applying for positions? This insightful panel features three unique voices – an industry leader, an educator, and a student – with their own perspectives on the barriers and opportunities facing the life sciences industry.

Moderator: TBD

TyNeisha Banks, MSA Principal, Perspectives
Holly Copeland, Senior Director, Corporate Social Responsibility, Sustainability & Impact, Horizon Therapeutics
Adrianna Emery, Perspectives Math & Science Academy Alumni; Horizon Scholar, Howard University

2:30 pm – 3:15 pm The Shift to Endemic: Living Alongside COVID-19

As scientists work to keep up with emerging variants and the world seeks to successfully transition from pandemic to endemic for COVID-19, both science and policy must partner to make deliberate choices. This panel will convene cross-functional experts to explore the practical and societal considerations that global public health authorities, scientists, regulatory bodies and manufacturers must weigh to successfully manage the ongoing threat such as: on which variants should efforts be focused and how will this evolve; will revaccination needs mimic other seasonal infectious respiratory diseases and if so, what is the potential role of combination vaccines; how will regulators approach review and approvals; what role will governments continue to play?

Silvia Taylor, Executive Vice President, Chief Communications Officer, Novavax

Professor Adrian Hill, Oxford University
John Moore, Ph.D., Professor of Microbiology and Immunology, Weill Medical College of Cornell University
John Trizzino, Executive Vice President, Chief Commercial Officer and Chief Business Officer, Novavax

3:30 pm – 4:15 pm Emerging Vaccine Opportunities in Modulating the Immune System

Cancer and other vexing medical conditions persist by evading detection by the body’s immune system. An emerging field of vaccine research and development known as immune system modulation aims to change this dynamic by stimulating or suppressing the immune system to help the body fight cancer, infection, or other diseases. This research has opened new opportunities to explore both the adaptive response and the innate response of the immune system to develop more effective vaccines. This panel combines leaders in the public research and commercial sectors to explore the challenges and opportunities in the emerging field of immune system modulation.

Moderator – TBD

Tim Clay
, Vice President, Head of Discovery Performance Unit Vaccines US, GSK
Geoffrey Lynn, Ph.D., Senior Vice President, Synthetic Immunotherapies
Chris Jewell,  Minta Martin Professor of Engineering (Endowed), University of Maryland

4:30 pm – 4:45 pm Closing Remarks

Marty Rosendale, Chief Executive Officer, Maryland Life Sciences
William Rees, Vice President, Translational Sciences, Horizon 

5:00 pm – 6:30 pm Cocktail Reception

Day 2  |  October 4, 2022

7:00 am – 7:55 am Registration Open – Breakfast and Networking
7:55 am – 8:00 am Welcome

Marty Rosendale, Chief Executive Officer, Maryland Life Sciences

8:00 am – 8:45 am The Patient Journey – Fireside Chat

This session will bring to life the patient journey of the cell therapy manufacturing process. Featuring an engaging discussion with Kite cell therapy manufacturing experts, we will highlight how cell therapy manufacturing produces and delivers individualized treatments in a rapid and reliable way for patients with difficult-to-treat blood cancers.

9:00 am – 4:00 pm BIO One-on-One Partnering
9:00 am – 9:45 am Automation in Biomanufacturing

The biomanufacturing industry has accumulated over 20 years of experience with monoclonal antibody manufacturing and over 10 years of experience with cell and gene therapies.  Automation that harnesses machine learning on the large data sets available can bring breakthroughs to the industry for both cost cutting and accelerated timeline purposes.  However automation in biomanufacturing is still not widely adopted.  In this session we aim to outline the necessary steps that the industry needs to take to make automation a useful and reliable tool.  Streamlining historical training data sets, automated design of experience (DOE) during process development, in-line analytics based manufacturing, self-controlled upstream bioreactor and downstream purification, and digital modeling of supply chain planning for mAb, cell and gene therapy fields will be discussed.

Jeffrey Hung, Ph.D., Chief Executive Officer, Naogene

Kevin GordonChief Digital Officer, OriBiotech
Eric Wu-NagySenior Automation Engineer, Takeda
Bruce Yu, Professor, University of Maryland, Professor and Director, The Bio- and Nano-Technology Center

9:00 am – 10:30 am Business of Bio Workshop A  | Maximizing Government Non-Dilutive Funding Programs

Learn about non-dilutive funding sources available from the U.S. Government (USG) for researchers and entrepreneurs.  The USG offers billions in non-dilutive funding and resources to help small businesses advance and commercialize promising translational biotech and life sciences research technologies.

Lili Portilla, Director, Office of Strategic Alliances,National Center for Advancing Translational Sciences, NIH
Becky Aistrup, M.B.A.,Managing Partner, BBC Entrepreneurial Training and Consulting

10:00  am – 10:45  am Workforce Readiness

How biotech/biopharma manufacturing is partnering with academia i.e. Kite with Hood College, FCC and UMBC and Catalent’s been having a lot of discussion with UMD, UMBC, etc. to leverage early talent and to influence training programs and curriculums.

Brad Stewart, Senior Vice President of Business Development, Montgomery County Economic Development Corporation

John Balchunas, Workforce Director, NIMBL

Jacob Hsu, Chief Executive Officer, Catalyte
Debborah Ricker, Ph.D., Provost and Vice President for Academic Affairs, Hood College
Kite representative

10:30 am – 12:00 pm Business of Bio Workshop B  |  Improving Biotech Company Value Through Strategic IP Management

This workshop will provide an overview of intellectual property assets and their value to the early-stage biotech company. An emphasis on strategic management will help the senior manager optimize their company’s value to potential investors, direct and manage efficient product development, and suggest growth potential through licensing. Participants will be encouraged to share their experiences

Peter Reczek, Founder, Centrala IPM, LLC
Scott Lloyd, Principal, Offit Kurman

11:00 am – 11:45 am Inclusion, Retention, and Advancement

Kevin Beverly, Chair, The Universities at Shady Grove

Maurice Jones, President and Chief Executive Officer, OneTen
Anne Khademian, Executive Director, Universities at Shady Grove, Associate Vice Chancellor for Academic Affairs, University System of Maryland
Marty Rosendale, Chief Executive Officer, Maryland Life Sciences
Yaminah Leggett-Wells, Senior Director, Alliance Management, Horizon

12:00 pm – 12:45 pm Networking Lunch
1:00 pm – 2:30 pm Business of Bio Workshop C

Part 1  |  Raising Capital

Brad Stewart
Senior Vice President of Business Development, Montgomery County Economic Development Corporation
Sally Allain, MSc., MBA, Head, JLABS @ Washington, DC and Interim Head JLABS North East, Johnson & Johnson Innovation – JLABS

Part 2  |  Raising Capital – Financing Strategy and Approach

This session will explore strategic and tactical considerations of equity financing for life science companies.  We will start with discussion on investor outreach, presentation materials and potential sources of equity capital.  The session also will broadly explore how to successfully raise equity in the context of a company’s life cycle/stage and tactical considerations too, such as issues to get right at any initial financing, readying for a due diligence process, understanding key lingo, and the anatomy and intricacies of a typical venture capital financing.

Matt Schwee
, Associate, Cooley
Lila Inman, Associate, Cooley